Compugen

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Compugen reports Q1 loss, showcases promising cancer immunotherapy approach

Compugen's Q1 2023 performance reflects a strategic focus on capital efficiency and milestone achievement.
Their innovative triple combination approach in cancer immunotherapy shows promise, with encouraging clinical benefits observed.
While managing R&D expenses and translating clinical benefits into marketable products are challenges, opportunities exist in disciplined cash deployment and exploration of biomarkers.
Overall, Compugen's financial discipline, promising clinical data, and strategic focus position them well for future growth in the oncology space.

Compugen (CGEN) reports positive ASCO results and solid financial standing

Compugen (CGEN) showcases promising results in cancer immunotherapy combinations, maintaining a strong financial position despite increased R&D expenses. The company's differentiated approach and focus on milestone achievement through 2024 position it well for future growth, although challenges in enrollment delays and managing expenses persist.

Compugen reports Q3 progress with promising clinical data and partnerships

Compugen's Q3 2023 performance reflects progress in clinical trials and financial stability with a cash balance of $57.5 million.
Strengths lie in innovative drug discovery approaches, successful clinical outcomes, and strategic partnerships.
Challenges include competitive enrollment landscape, cost management, and market acceptance of novel treatments.
Opportunities exist in upcoming data reporting, novel drug targets, and collaborations for future growth and success.

Compugen reports robust earnings and strategic partnerships drive growth

Compugen's Q4 2023 performance reflects strong financial results and notable achievements in clinical advancements and partnerships.
The company's financial stability, strategic focus, and robust pipeline position them well for future growth and innovation.
While facing challenges in clinical trial outcomes and partnership strategies, Compugen has opportunities to drive further growth through data insights and collaborations.

Compugen reports solid Q1 performance, poised for growth in 2024

Compugen's Q1 2024 performance reflects financial stability, operational efficiency, and progress in advancing key drug candidates towards clinical trials, underpinned by a robust AI discovery platform and strategic partnerships.
While challenges like ongoing R&D investments and achieving profitability persist, opportunities in milestone achievements, data readouts, and strategic collaborations position Compugen for future growth and value creation.
Navigating the biopharmaceutical landscape with innovation, financial discipline, and strategic foresight, Compugen stands poised to capitalize on market opportunities, drive pipeline progression, and enhance shareholder value.

Compugen reports Q2 revenue of $6.7M, highlights innovative drug strategies

Compugen's Q2 2024 performance reflects steady revenue generation and prudent financial management. The company's strengths in innovative drug development and strategic collaborations present promising growth opportunities. Addressing challenges in clinical evidence and cash burn will be crucial for sustained success.

Compugen reports solid Q3 earnings, advances promising ovarian cancer therapies

Compugen's strong financial position, promising clinical data on multiple therapies, and strategic focus on ovarian cancer treatment advancements position the company for potential growth. Challenges lie in maintaining treatment efficacy and navigating regulatory discussions for future developments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

When the financial markets enter their once-a-decade crisis mode, it often feels impossible to think rationally and to make normal investing decisions.

Compugen Projected to Rise Over 100% in Key Analyst Report

Two patients treated with one of the biotech's drugs had partial responses.

Here's Why Compugen Jumped Higher Today

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2019 Results - Earnings Call Transcript

Compugen Ltd.: Upcoming Catalysts In 2020 And 2021

Glu Mobile

GameStop

Groupon

Interpace Diagnostics

Meet Group

OrganiGram Holdings Inc.

RTI Surgical

Synlogic

Zynga

With stocks at all time highs and after the Dow rose more than 22% and the S&P 500 rose over 28% in 2019, many investors have yet to make many changes in the portfolios for what could be another solid 2020.

10 Stocks Trading Under $10 With Massive Upside Potential in 2020

Compugen shares rebounded Thursday after Cantor Fitzgerald initiated coverage with an Overweight rating and a $10 price target.

Compugen Stock Rebounds After Analyst Sees 60% Upside

ACADIA Pharma

Cue Biopharma

Epizyme

uniQure

The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.

5 Biotech Stocks That Have More Than Doubled This Year

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2019 Results - Earnings Call Transcript

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Compugen (CGEN) Upgraded to Buy: Here's What You Should Know

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q2 2019 Results - Earnings Call Transcript

Compugen (CGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Compugen (CGEN) Upgraded to Strong Buy: Here's What You Should Know

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q1 2019 Results - Earnings Call Transcript

News for Compugen Stock (CGEN)